179 related articles for article (PubMed ID: 19261472)
1. Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.
Yan YL; Miller MT; Cao Y; Cohen SM
Bioorg Med Chem Lett; 2009 Apr; 19(7):1970-6. PubMed ID: 19261472
[TBL] [Abstract][Full Text] [Related]
2. Zinc-binding groups modulate selective inhibition of MMPs.
Agrawal A; Romero-Perez D; Jacobsen JA; Villarreal FJ; Cohen SM
ChemMedChem; 2008 May; 3(5):812-20. PubMed ID: 18181119
[TBL] [Abstract][Full Text] [Related]
3. A bioinorganic perspective on matrix metalloproteinase inhibition.
Puerta DT; Cohen SM
Curr Top Med Chem; 2004; 4(15):1551-73. PubMed ID: 15579096
[TBL] [Abstract][Full Text] [Related]
4. Investigating chelating sulfonamides and their use in metalloproteinase inhibitors.
Tanakit A; Rouffet M; Martin DP; Cohen SM
Dalton Trans; 2012 Jun; 41(21):6507-15. PubMed ID: 22411188
[TBL] [Abstract][Full Text] [Related]
5. Potent, selective pyrone-based inhibitors of stromelysin-1.
Puerta DT; Mongan J; Tran BL; McCammon JA; Cohen SM
J Am Chem Soc; 2005 Oct; 127(41):14148-9. PubMed ID: 16218585
[TBL] [Abstract][Full Text] [Related]
6. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.
Puerta DT; Lewis JA; Cohen SM
J Am Chem Soc; 2004 Jul; 126(27):8388-9. PubMed ID: 15237990
[TBL] [Abstract][Full Text] [Related]
7. Enzymatic activation of a matrix metalloproteinase inhibitor.
Major Jourden JL; Cohen SM
Chem Commun (Camb); 2010 Feb; 46(8):1241-3. PubMed ID: 20449263
[TBL] [Abstract][Full Text] [Related]
8. Design, modelling, synthesis and biological evaluation of peptidomimetic phosphinates as inhibitors of matrix metalloproteinases MMP-2 and MMP-8.
Bianchini G; Aschi M; Cavicchio G; Crucianelli M; Preziuso S; Gallina C; Nastari A; Gavuzzo E; Mazza F
Bioorg Med Chem; 2005 Aug; 13(15):4740-9. PubMed ID: 15935680
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of novel oxazoline MMP inhibitors.
Cook GR; Manivannan E; Underdahl T; Lukacova V; Zhang Y; Balaz S
Bioorg Med Chem Lett; 2004 Oct; 14(19):4935-9. PubMed ID: 15341955
[TBL] [Abstract][Full Text] [Related]
10. Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).
Zhang YM; Fan X; Yang SM; Scannevin RH; Burke SL; Rhodes KJ; Jackson PF
Bioorg Med Chem Lett; 2008 Jan; 18(1):405-8. PubMed ID: 17980583
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloprotease inhibitors: design from structure.
Borkakoti N
Biochem Soc Trans; 2004 Feb; 32(Pt 1):17-20. PubMed ID: 14748704
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX
Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329
[TBL] [Abstract][Full Text] [Related]
13. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group.
Farkas E; Katz Y; Bhusare S; Reich R; Röschenthaler GV; Königsmann M; Breuer E
J Biol Inorg Chem; 2004 Apr; 9(3):307-15. PubMed ID: 14762707
[TBL] [Abstract][Full Text] [Related]
14. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.
Skiles JW; Gonnella NC; Jeng AY
Curr Med Chem; 2001 Mar; 8(4):425-74. PubMed ID: 11172697
[TBL] [Abstract][Full Text] [Related]
15. The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.
Steinman DH; Curtin ML; Garland RB; Davidsen SK; Heyman HR; Holms JH; Albert DH; Magoc TJ; Nagy IB; Marcotte PA; Li J; Morgan DW; Hutchins C; Summers JB
Bioorg Med Chem Lett; 1998 Aug; 8(16):2087-92. PubMed ID: 9873491
[TBL] [Abstract][Full Text] [Related]
16. Quest for selectivity in inhibition of matrix metalloproteinases.
Brown S; Meroueh SO; Fridman R; Mobashery S
Curr Top Med Chem; 2004; 4(12):1227-38. PubMed ID: 15320723
[TBL] [Abstract][Full Text] [Related]
17. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
Levin M; Udi Y; Solomonov I; Sagi I
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
[TBL] [Abstract][Full Text] [Related]
18. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.
Scozzafava A; Supuran CT
J Med Chem; 2000 Oct; 43(20):3677-87. PubMed ID: 11020282
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors.
Nuti E; Tuccinardi T; Rossello A
Curr Pharm Des; 2007; 13(20):2087-100. PubMed ID: 17627541
[TBL] [Abstract][Full Text] [Related]
20. Efficient synthesis of 5-amido-3-hydroxy-4-pyrones as inhibitors of matrix metalloproteinases.
Yan YL; Cohen SM
Org Lett; 2007 Jun; 9(13):2517-20. PubMed ID: 17521196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
